Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors |
| |
Authors: | Emmet McCormack Katherine J Adams Namir J Hassan Akhil Kotian Nikolai M Lissin Malkit Sami Maja Mujić Tereza Osdal Bjørn Tore Gjertsen Deborah Baker Alex S Powlesland Milos Aleksic Annelise Vuidepot Olivier Morteau Deborah H Sutton Carl H June Michael Kalos Rebecca Ashfield Bent K Jakobsen |
| |
Institution: | 1. Haematology Section, Institute of Medicine, University of Bergen, Bergen, Norway 4. Immunocore Ltd, 57C Milton Park, Abingdon, Oxfordshire, OX14 4RX, UK 5. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 3. KinN Therapeutics AS, Haukeland University Hospital, 9th Floor Laboratory Building, Bergen, Norway 2. Haematology Section, Department of Internal Medicine, Haukeland University Hospital, Bergen, Norway 6. Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
|
| |
Abstract: | NY-ESO-1 and LAGE-1 are cancer testis antigens with an ideal profile for tumor immunotherapy, combining up-regulation in many cancer types with highly restricted expression in normal tissues and sharing a common HLA-A*0201 epitope, 157–165. Here, we present data to describe the specificity and anti-tumor activity of a bifunctional ImmTAC, comprising a soluble, high-affinity T-cell receptor (TCR) specific for NY-ESO-1157–165 fused to an anti-CD3 scFv. This reagent, ImmTAC-NYE, is shown to kill HLA-A2, antigen-positive tumor cell lines, and freshly isolated HLA-A2- and LAGE-1-positive NSCLC cells. Employing time-domain optical imaging, we demonstrate in vivo targeting of fluorescently labelled high-affinity NYESO-specific TCRs to HLA-A2-, NY-ESO-1157–165-positive tumors in xenografted mice. In vivo ImmTAC-NYE efficacy was tested in a tumor model in which human lymphocytes were stably co-engrafted into NSG mice harboring tumor xenografts; efficacy was observed in both tumor prevention and established tumor models using a GFP fluorescence readout. Quantitative RT-PCR was used to analyze the expression of both NY-ESO-1 and LAGE-1 antigens in 15 normal tissues, 5 cancer cell lines, 10 NSCLC, and 10 ovarian cancer samples. Overall, LAGE-1 RNA was expressed at a greater frequency and at higher levels than NY-ESO-1 in the tumor samples. These data support the clinical utility of ImmTAC-NYE as an immunotherapeutic agent for a variety of cancers. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|